RVV (RVV) News
Follow RVV (RVV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programsTORONTO, ON / / September 15, 2026 / Revive Therapeutics Ltd. ("Reviv
NEWS | Sep 15, 2026, 01:41 PM UTC
L
Revive Therapeutics proposes shares for debt settlement
Revive Therapeutics announces a proposed shares-for-debt settlement, with no further terms, amount, or catalyst supplied in the alert.
REGULATION | Aug 19, 2026, 06:35 PM UTC
M
Revive Therapeutics Reports Positive Results
Revive Therapeutics reports positive results from DRDC Bucillamine Nerve-Agent Research Study
EQUITY | Aug 12, 2026, 11:55 AM UTC